BioLine Rx Q3 EPS $(0.03) Beats $(0.64) Estimate

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.64) by 95.31 percent. This is a 50 percent increase over losses of $(0.06) per share from the same

Benzinga · 11/11/2019 12:16

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.64) by 95.31 percent. This is a 50 percent increase over losses of $(0.06) per share from the same period last year.